Award
Alberta Purchasing #NOA 2025-0025
AP 20-202 Adjuvant Formulation (40µG/ml SLA; 4% Squalene oil; 0.6ml fill volume) for HCV vaccine
Recipient
Access to Advanced Health Institute
Award Amount
$396,181.00
Ceiling
$396,181.00
Awarded
February 03, 2025
Identifier
NOA 2025-0025
The University of Alberta awarded a contract to Access to Advanced Health Institute for the formulation of a clinical-grade adjuvant SLA-SE used in Phase I HCV vaccine trials. The contract, valued at approximately $396,181, was a sole source procurement to support departmental research and vaccine development. The award facilitates the production of a specific adjuvant (40µG/ml SLA, 4% Squalene oil, 0.6ml fill volume) critical for advancing hepatitis C virus (HCV) vaccine research. The procurement was managed through the Alberta Purchasing feed, with the delivery location in Edmonton, Alberta. The contract was awarded on February 3, 2025.
Description
Award for formulation of clinical grade adjuvant SLA-SE used in Phase I HCV vaccine human clinical trial, critical for vaccine development and departmental research at University of Alberta.